云顶新耀,拿下六个原研!

药通社
Dec 17

12月11日,云顶新耀宣布与海森生物签署两项战略合作协议,其一是6款成熟产品的商业化服务协议;其二是正在研发的PCSK9抑制剂“莱达西贝普”后续大中华区的开发、注册、商业化独家许可协议。经查,海森生物和云顶新耀背后均是康桥资本操控,此次合作可理解为左右手互助。先看商业化合作的六款成熟产品,全都是海森生物这些年从各个外资手上收购的原研药,分别是:罗氏的头孢曲松钠“罗氏芬”、默克的生长抑素“思他宁”,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10